Sanofi Consumer Healthcare India Limited (BSE:544250 | NSE: SANOFICONR) posted robust Q1’26 results, with revenue climbing 33% year-on-year to ₹2,292 million and profit after tax (PAT) rising 36% to ₹678 million.
Domestic sales grew 15.5%, fueled by relaunches of recalled products, outpacing market growth with gains in share and volume. Exports soared 144% from a low base, boosting overall performance.
Himanshu Bakshi, Managing Director, said, “Our performance this quarter reflects consistent, disciplined execution across our key markets. Domestic business outpaced the market, delivering both market share gains and volume growth, while exports made a meaningful contribution to overall results. Guided by science and driven by purpose, we remain committed to simplifying self-care and making it more accessible and effective for consumers.”
The results underscore Sanofi’s focus on science-backed self-care amid India’s expanding consumer health market.
